CoChat
Sign Up
Cited by 10Viral-associated cancers and disordersHead and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; its reference list is not available.

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy

Open access
Lin, Shaoyan, Zhou, Huaqiang, Chen, Gang, Xue, Jinhui, Liu, Qianwen, Li, Jianing, Yang, Yanhua, Zhao, Yuanyuan, Bao, Hua, Huang, Yan, Ma, Yuxiang, Zhao, Hongyun·2024·BMC Cancer
DOI 10.1186/s12885-024-12564-4PMC PMC11223362
Open this paper in CoChat — free account

Abstract

Purpose: Patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) have proven benefit from anti-programmed cell death 1 (anti-PD-1) monotherapy. Here, we retrospectively analyze the association of plasma Epstein-Barr virus (EBV) DNA load and tumor viral lytic genome with clinical outcome from 2 registered phase I trials. Methods: Patients with RM-NPC from Checkmate 077 (nivolumab phase I trial in China) and Camrelizumab phase I trial between March 2016 and January 2018 were enrolled. Baseline EBV DNA titers were tested in 68 patients and EBV assessment was performed in 60 patients who had at least 3 post-baseline timepoints of EBV data and at least 1 post-baseline timepoint of radiographic assessment. We defined “EBV response” as 3 consecutive timepoints of load below 50% of baseline, and “EBV progression” as 3 consecutive timepoints of load above 150% of baseline. Whole-exome sequencing was performed in 60 patients with available tumor samples. Results: We found that the baseline EBV DNA load was positively correlated with tumor size (spearman p < 0.001). Both partial response (PR) and stable disease (SD) patients had significantly lower EBV load than progression disease (PD) patients. EBV assessment was highly consistent with radiographic evaluation. Patients with EBV response had significantly improved overall survival (OS) than patients with EBV progression (log-rank p = 0.004, HR = 0.351 [95% CI: 0.171–0.720], median 22.5 vs. 11.9 months). The median time to initial EBV response and progression were 25 and 36 days prior to initial radiographic response and progression, respectively. Patients with high levels of EBV lytic genomes at baseline, including BKRF2, BKRF3 and BKRF4, had better progression-free survival (PFS) and OS. Conclusion: In summary, early clearance of plasma EBV DNA load and high levels of lytic EBV genes were associated with better clinical outcome in patients with RM-NPC receiving anti-PD-1 monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-024-12564-4

Cites

Statistics

Figures

Fig. 1 Baseline Epstein-Barr virus (EBV) load and clinical outcome. A. Spearman correlation between tumor size and plasma EBV copy number at baseline. B. Boxplot of log10 baseline viral load by Response Evaluation Criteria in Solid Tumors group. ORR, objective response rate; PD, progression disease; PR, partial remission; SD, stable disease
Fig. 1 Baseline Epstein-Barr virus (EBV) load and clinical outcome. A. Spearman correlation between tumor size and plasma EBV copy number at baseline. B. Boxplot of log10 baseline viral load by Response Evaluation Criteria in Solid Tumors group. ORR, objective response rate; PD, progression disease; PR, partial remission; SD, stable diseaseCC BY · PubMed Central
Fig. 2 Change of EBV load during treatment and response to immunotherapy. A. Waterfall plot of change from baseline in tumor size for patients with nasopharyngeal carcinoma. B. Change from baseline in EBV viral load for patients with PD and PR. C. OS curve of patients with EBV response vs. those with EBV progression. D. Swimmer plot that shows time to initial EBV response/progression and RECIST response/progression in PR and PD patients. RECIST, Response Evaluation Criteria in Solid Tumors; PD, progression disease; PR, partial remission; SD, stable disease; EBV, Epstein-Barr virus; OS, overall survival
Fig. 2 Change of EBV load during treatment and response to immunotherapy. A. Waterfall plot of change from baseline in tumor size for patients with nasopharyngeal carcinoma. B. Change from baseline in EBV viral load for patients with PD and PR. C. OS curve of patients with EBV response vs. those with EBV progression. D. Swimmer plot that shows time to initial EBV response/progression and RECIST response/progression in PR and PD patients. RECIST, Response Evaluation Criteria in Solid Tumors; PD, progression disease; PR, partial remission; SD, stable disease; EBV, Epstein-Barr virus; OS, overall survivalCC BY · PubMed Central
Fig. 3 EBV and RECIST assessment of 1 PR and 1 PD patients. A. Tumor size and plasma EBV load change over time in a PD patient. EBV load was on log10 scale. B. Tumor size and plasma EBV load change over time in a PR patient. EBV load was on log10 scale. EBV: Epstein-Barr virus; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progression disease; PR: partial remission
Fig. 3 EBV and RECIST assessment of 1 PR and 1 PD patients. A. Tumor size and plasma EBV load change over time in a PD patient. EBV load was on log10 scale. B. Tumor size and plasma EBV load change over time in a PR patient. EBV load was on log10 scale. EBV: Epstein-Barr virus; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progression disease; PR: partial remissionCC BY · PubMed Central
Fig. 4 Levels of BKRF2, BKRF3 and BKRF4 in patients with durable clinical benefit (DCB) and non-durable clinical benefit (NDB)
Fig. 4 Levels of BKRF2, BKRF3 and BKRF4 in patients with durable clinical benefit (DCB) and non-durable clinical benefit (NDB)CC BY · PubMed Central
Fig. 5 The effect of levels of BKRF2, BKRF3 and BKRF4 on patients’ progression-free survival (PFS) and overall survival (OS). PFS (A) and OS (B) curve stratified by median levels of BKRF2. PFS (C) and OS (D) curve stratified by median levels of BKRF3. PFS (E) and OS (F) curve stratified by median levels of BKRF4
Fig. 5 The effect of levels of BKRF2, BKRF3 and BKRF4 on patients’ progression-free survival (PFS) and overall survival (OS). PFS (A) and OS (B) curve stratified by median levels of BKRF2. PFS (C) and OS (D) curve stratified by median levels of BKRF3. PFS (E) and OS (F) curve stratified by median levels of BKRF4CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 38 · Cited by 10

Research works printed but not linked: 35

  1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. · DOI
  2. Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, et al. NCCN Guidelines® insights: Head and Neck cancers, Version 1.2022. J Natl Compr Canc Netw. 2022;20(3):224–34. · DOI
  3. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al. Antitumor Activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412–8. · DOI
  4. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–50. · DOI
  5. Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704–12. · DOI
  6. Adkins DR, Haddad RI. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review. Cancer Treat Rev. 2022;109:102428. · DOI
  7. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–46. · DOI · Paper page
  8. Tang LQ, Chen QY, Guo SS, Chen WH, Li CF, Zhang L, Lai XP, He Y, Xu YX, Hu DP, et al. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer. 2014;111(6):1102–11. · DOI
  9. Münz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019;17(11):691–700. · DOI
  10. Jha HC, Pei Y, Robertson ES. Epstein-Barr Virus: diseases linked to infection and Transformation. Front Microbiol. 2016;7:1602. · DOI
  11. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci 2017, 372(1732). · DOI
  12. Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8:14121. · DOI
  13. Yang CF, Yang GD, Huang TJ, Li R, Chu QQ, Xu L, Wang MS, Cai MD, Zhong L, Wei HJ, et al. EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop. Oncogene. 2016;35(26):3419–31. · DOI
  14. Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, Cheng YJ, Westra WH, Chen CJ, Hildesheim A, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66(16):7999–8006. · DOI
  15. Chen LW, Hung CH, Wang SS, Yen JB, Liu AC, Hung YH, Chang PJ. Expression and regulation of the BKRF2, BKRF3 and BKRF4 genes of Epstein-Barr virus. Virus Res. 2018;256:76–89. · DOI
  16. Su MT, Liu IH, Wu CW, Chang SM, Tsai CH, Yang PW, Chuang YC, Lee CP, Chen MR. Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex. J Virol. 2014;88(16):8883–99. · DOI
  17. Masud H, Watanabe T, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T. Epstein-Barr Virus BKRF4 gene product is required for efficient progeny production. J Virol 2017, 91(23). · DOI
  18. Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, Chen JL, Wang YQ, Han F, Wang FH. Association of plasma Epstein-Barr Virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open. 2022;5(3):e220587. · DOI
  19. Ma Y, Chen X, Wang A, Zhao H, Lin Q, Bao H, Zhang Y, Hong S, Tang W, Huang Y et al. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. J Immunother Cancer 2021, 9(3). · DOI
  20. Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, et al. A phase I/II open-label study of Nivolumab in previously treated Advanced or recurrent nasopharyngeal carcinoma and other solid tumors. Oncologist. 2019;24(7):891–e431. · DOI
  21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. · DOI · Paper page
  22. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9. · DOI
  23. Fang H, Bergmann EA, Arora K, Vacic V, Zody MC, Iossifov I, O’Rawe JA, Wu Y, Jimenez Barron LT, Rosenbaum J, et al. Indel variant analysis of short-read sequencing data with Scalpel. Nat Protoc. 2016;11(12):2529–48. · DOI
  24. Chou LS, Liu CS, Boese B, Zhang X, Mao R. DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model. Clin Chem. 2010;56(1):62–72. · DOI
  25. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, Liu T, Huang Z, Feng Y, Sun X, Xiong Z, et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J Virol. 2011;85(21):11291–9. · DOI
  26. Kwok H, Wu CW, Palser AL, Kellam P, Sham PC, Kwong DL, Chiang AK. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol. 2014;88(18):10662–72. · DOI
  27. Zhou X, Yang Y, Ou X, Xu T, Shen C, Hu C. Interplay of Tumor Spread, volume and Epstein-Barr Virus DNA in nasopharyngeal carcinoma: feasibility of an integrative risk stratification Scheme. J Cancer. 2018;9(22):4271–8. · DOI
  28. Bureau M, Chatellier T, Perennec T, Goronflot T, Greilsamer C, Chene AL, Affi R, Frampas E, Bennouna J, Pons-Tostivint E. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab. Cancer Immunol Immunotherapy: CII. 2022;71(7):1747–56. · DOI
  29. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with Melanoma Treated with Pembrolizumab. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(20):4960–7. · DOI
  30. Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Reviews Clin Oncol. 2017;14(3):187–92. · DOI
  31. Ahmed N, Abusalah M, Farzand A, Absar M, Yusof NY, Rabaan AA, AlSaihati H, Alshengeti A, Alwarthan S, Alsuwailem HS et al. Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: emphasis on the latent Gene products of EBV. Med (Kaunas) 2022, 59(1). · DOI
  32. Martel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol. 1995;76(Pt 6):1401–8. · DOI
  33. Shen Y, Zhang S, Sun R, Wu T, Qian J. Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients. Emerg Microbes Infect. 2015;4(3):e20. · DOI
  34. McKenzie J, El-Guindy A. Epstein-Barr Virus Lytic Cycle Reactivation. Curr Top Microbiol Immunol. 2015;391:237–61.
  35. Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J, et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020;1(2):210–21. · DOI

Metadata

Authors
Lin, S., Zhou, H., Chen, G., Xue, J., Liu, Q., Li, J., Yang, Y., Zhao, Y., Bao, H., Huang, Y., Ma, Y., & Zhao, H.
Affiliations
Sun Yat-sen University (CN)
Corresponding author
  • Huang, Yan
  • Ma, Yuxiang
  • Zhao, Hongyun
ORCID
Venue
BMC Cancer
Publisher
Springer Science and Business Media LLC
Published
2024-07-03
Volume
24
Issue
1
Pages
797-797
ISSN
1471-2407 (ISSN-L)
DOI
10.1186/s12885-024-12564-4
PMC
PMC11223362
OpenAlex
W4400289811
Cited by
10
References
38
Citations by year
2026: 3 · 2025: 7
FWCI
1.70
Type
journal article
Language
en
Update notices
correction (2026-08-12)
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Nature Science Foundation of China (82002409, 82073396)
  • Guangdong Basic and Applied Basic Research Foundation (2020A1515010020)
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
nasopharyngeal carcinoma, recurrent or metastatic nasopharyngeal carcinoma, Epstein-Barr virus, anti-PD-1 monotherapy, nivolumab, camrelizumab, predictive biomarkers, overall survival, progression-free survival
MeSH terms
Nasopharyngeal Carcinoma, Nivolumab, Immune Checkpoint Inhibitors, Adult, Aged, DNA, Viral, Herpesvirus 4, Human, Female, Humans, Male, Middle Aged, Nasopharyngeal Neoplasms, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Genome, Viral, Treatment Outcome, Viral Load, Epstein-Barr Virus Infections, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. https://app.cochat.ai/papers/10.1186/s12885-024-12564-4
The paper
Lin, S., Zhou, H., Chen, G., Xue, J., Liu, Q., Li, J., Yang, Y., Zhao, Y., Bao, H., Huang, Y., Ma, Y., & Zhao, H. (2024). Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. BMC Cancer. https://doi.org/10.1186/s12885-024-12564-4